secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verve Therapeutics, Inc. (—)
CIK:        0001840574
Form:       8-K
Filed at:   2025-07-25T23:59:59+00:00
Accession:  0001193125-25-165462
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eli Lilly completes acquisition of Verve Therapeutics for $10.50/share plus CVR
-------------------------------------------------------------------------------

- Tender offer expired July 23, 2025, with 55.7% of shares validly tendered; all conditions satisfied.
- Merger completed July 25, 2025; Verve became an indirect wholly-owned subsidiary of Eli Lilly.
- Stockholders received $10.50 per share in cash plus one CVR with potential $3.00 milestone payment.
- Verve common stock delisted from Nasdaq; registration to be terminated.
- Board of directors replaced with Eli Lilly designees; prior directors resigned.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840574/000119312525165462/0001193125-25-165462-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840574/000119312525165462/d71385d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-165462

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer